title: Effects of KP-496, a novel dual antagonist for cysteinyl leukotriene receptor 1 and thromboxane A2 receptor, on Sephadex-induced airway inflammation in rats.
abstract: Bronchial asthma is characterized by chronic airway inflammation. Eosinophils are involved in airway inflammation and play crucial roles in asthma. There is accumulating evidence to suggest contributions of cysteinyl leukotrienes (cysLTs) and thromboxane (TX) A(2) to the recruitment of eosinophils into lung in asthmatics. KP-496 is a novel dual antagonist for CysLT receptor type 1 and TXA(2) receptors. The aim of this study was to evaluate the anti-inflammatory effects of KP-496 on Sephadex-induced airway inflammation. Sephadex suspension was intratracheally injected into rats. Amounts of regulated on activation, normal T cell expressed and secreted (RANTES) and eotaxin, and numbers of infiltrating cells in bronchoalveolar lavage fluid were measured 24 and 48 h after Sephadex injection, respectively. KP-496 (30, 100 microg/head) was intratracheally administered to rats 1 h before and 7 h after Sephadex injection. KP-496 and prednisolone (10 mg/kg, per os) exhibited significant inhibitory effects on infiltration of total cells and eosinophils into lung. Production of RANTES was significantly inhibited by KP-496 and prednisolone. Production of eotaxin was significantly inhibited by prednisolone. KP-496 also inhibited the production of eotaxin, though this effect was not significant. These results demonstrate that KP-496 exhibited the anti-inflammatory effects by inhibiting infiltration of inflammatory cells and productions of RANTES and eotaxin.
authors.affiliation: Pharmacology Department, Central Research Laboratories, Kaken Pharmaceutical Co., Ltd, Kyoto, Japan. ishimura_masakazu@kaken.co.jp
authors.forename: Masakazu
authors.initials: M
authors.lastname: Ishimura
authors.forename: Takashi
authors.initials: T
authors.lastname: Maeda
authors.forename: Sayuri
authors.initials: S
authors.lastname: Kataoka
authors.forename: Masahiro
authors.initials: M
authors.lastname: Suda
authors.forename: Shigeo
authors.initials: S
authors.lastname: Kurokawa
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Hiyama
mesh_terms: D000818:Animals; D001249:Asthma / Q000276:immunology / Q000517:prevention & control*; D001565:Benzoates / Q000494:pharmacology*; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology / Q000276:immunology; D018946:Chemokine CCL5 / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D003911:Dextrans; D004804:Eosinophils / Q000166:cytology; D007249:Inflammation / Q000139:chemically induced / Q000276:immunology*; D007958:Leukocyte Count; D020024:Leukotriene Antagonists / Q000494:pharmacology*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D018077:Receptors, Leukotriene / Q000096:biosynthesis*; D044244:Receptors, Thromboxane A2, Prostaglandin H2 / Q000037:antagonists & inhibitors*; D013844:Thiazoles / Q000494:pharmacology*
chemical_list: D001565:Benzoates; D018946:Chemokine CCL5; D003911:Dextrans; C528276:KP-496; D020024:Leukotriene Antagonists; D018077:Receptors, Leukotriene; D044244:Receptors, Thromboxane A2, Prostaglandin H2; D013844:Thiazoles; C025614:sephadex; C083169:leukotriene D4 receptor